| 001 | 241121 | ||
| 005 | 20240229162312.0 | ||
| 024 | 7 | _ | |a 10.1111/ddg.14944_g |2 doi |
| 024 | 7 | _ | |a pmid:36721945 |2 pmid |
| 024 | 7 | _ | |a 1610-0379 |2 ISSN |
| 024 | 7 | _ | |a 0301-0481 |2 ISSN |
| 024 | 7 | _ | |a 0303-8173 |2 ISSN |
| 024 | 7 | _ | |a 1439-0353 |2 ISSN |
| 024 | 7 | _ | |a 1563-2571 |2 ISSN |
| 024 | 7 | _ | |a 1610-0387 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2023-00241 |
| 041 | _ | _ | |a German |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Chatzikonstantinou, Georgios |b 0 |
| 245 | _ | _ | |a Customized 3D-printed molds for high dose-ratebrachytherapy in facial skin cancer: First clinical experience.[3D-gedruckte Moulagen für die individualisierte HDR-Brachytherapie kutaner Malignome im Gesichtsbereich: Erste klinische Erfahrungen.] |
| 260 | _ | _ | |a Berlin |c 2023 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1705069007_11431 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a english version: Doi:10.1111/ddg.14944 |
| 520 | _ | _ | |a Background and Objective: Radiotherapy of elderly, frail patients with facial skin cancer in proximity to critical organs is challenging. This is the first report on clinical experience with facial skin cancer treated by individualized 3D-printer-basedmold high-dose-rate (HDR) brachytherapy (BT). Patients and Methods: Fifteen patients not eligible for radical surgery or definitive external beam radiotherapy (EBRT) were treated with 3D-printer-based moldHDR-BT. Patient selection and treatment were in accordance with multidisciplinary tumor board recommendations. Clinicalresponse, toxicity and cosmesis were analyzed. Results: Median age was 77 years. Histology revealed squamous cell carcinomain seven, basal cell carcinoma in five, melanoma in situ in one, Lentigo maligna in one, and melanoma in one patient, respectively. Median prescription dosewas 39 Gy delivered in once-daily fractions of 3 Gy. After a median follow-up of 12.2 months, local recurrence was observed in one patient with melanoma in situ. Apart from one grade 4 cataract, no other >grade 2 late toxicity was documented. Conclusions: HDR-BT with 3D-printer-based molds for facial skin cancer is a well-tolerated and safe treatment option for elderly, frail patients not eligible for radicalsurgery or definitive EBRT due to functional inoperability or tumor location. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Diefenhardt, Markus |b 1 |
| 700 | 1 | _ | |a Fleischmann, Maximilian |b 2 |
| 700 | 1 | _ | |a Meissner, Markus |b 3 |
| 700 | 1 | _ | |a Scherf, Christian |b 4 |
| 700 | 1 | _ | |a Trommel, Martin |b 5 |
| 700 | 1 | _ | |a Ramm, Ulla |b 6 |
| 700 | 1 | _ | |a Rödel, Claus |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Tselis, Nikolaos |b 8 |
| 700 | 1 | _ | |a Licher, Jörg |b 9 |
| 773 | _ | _ | |a 10.1111/ddg.14944_g |g Vol. 21, no. 1, p. 35 - 43 |0 PERI:(DE-600)2099463-1 |n 1 |p 35 - 43 |t Journal der Deutschen Dermatologischen Gesellschaft |v 21 |y 2023 |x 1610-0379 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:241121 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2022-11-25 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-25 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-25 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J DTSCH DERMATOL GES : 2022 |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-25 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-25 |
| 920 | 1 | _ | |0 I:(DE-He78)FM01-20160331 |k FM01 |l DKTK Koordinierungsstelle Frankfurt |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)FM01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::